Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

HOOKIPA Pharma Inc. Announces Clinical Collaboration with Merck & Co., Inc., Kenilworth, NJ., USA to evaluate HB-200 in combination with KEYTRUDA« (pembrolizumab) in patients with advanced head and neck cancers

09/15/2021 | 07:00am EDT

HOOKIPA Pharma Inc. announced it has entered into a clinical collaboration and supply agreement with Merck & Co., Inc., Kenilworth, NJ., USA (known as MSD outside of the United States and Canada) to evaluate the combination of HB-200, a novel arenaviral immunotherapeutic, and Merck & Co., Inc., Kenilworth, NJ., USA’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) as first-line treatment for patients with advanced head and neck squamous cell carcinoma (HNSCC). The collaboration has been initiated based on promising data from the ongoing HB-200 Phase 1/2 clinical trial (NCT04180215) in advanced HPV16+ cancers. As reported at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, 15 patients with metastatic head and neck cancers were eligible for the efficacy analysis, as of data cut-off. HB-201 monotherapy showed an 18% overall response rate and median progression-free survival of 3.45 months in heavily pretreated head and neck cancer patients, better than current 2nd-line treatment. In addition, preliminary data on HB-201/HB-202 therapy showed a disease control rate of 100% (4/4 patients). Importantly, the Phase 1 data on 38 evaluable patients showed that HB-200 therapy has a favorable safety profile in heavily pre-treated patients with HPV16+ cancers, underlining its potential as a monotherapy and in possible combination with checkpoint inhibitors. With a HB-200 program data read-out anticipated by Fourth Quarter 2021, HOOKIPA anticipates initiating a Phase 2 trial with HB-200 in combination with KEYTRUDA in 2022. Additional Phase 2 expansion cohorts are also planned to start in First Quarter 2022.

ę S&P Capital IQ 2021
All news about MERCK & CO., INC.
10/15MERCK : And Co. Gets European Medicines Agency's Positive Opinions on Pneumonia Vaccine, C..
10/15MERCK : Receives Positive Opinions From European Medicines Agency on Pneumonia Vaccine, Ca..
10/15Merck, Eisai Get CHMP Backing for Lenvima-Keytruda Combo in Two Cancers
10/15MERCK : and Eisai Receive Positive EU CHMP Opinions for KEYTRUDA« (pembrolizumab) Plus LEN..
10/15MERCK : Receives Positive CHMP Opinion for VAXNEUVANCE™ (Pneumococcal 15-valent Conj..
10/15Merck Gets CHMP Positive Opinion for Vaxneuvance Vaccine
10/15MERCK : US FDA To Review Merck & Co.'s COVID-19 Antiviral Drug For Approval In Late Novemb..
10/14MERCK : FDA to Review Merck's Emergency Use Authorization Request For Molnupiravir COVID-1..
10/14MERCK : Nov 30th FDA Advisory Committee meeting to Discuss Merck & Ridgeback's COVID-19 An..
10/14MERCK : Acceleron Pharma Shareholder Says Merck & Co.'s Offer Significantly Undervalues Co..
More news
Analyst Recommendations on MERCK & CO., INC.
More recommendations
Financials (USD)
Sales 2021 48 042 M - -
Net income 2021 13 209 M - -
Net Debt 2021 17 557 M - -
P/E ratio 2021 16,5x
Yield 2021 3,31%
Capitalization 198 B 198 B -
EV / Sales 2021 4,49x
EV / Sales 2022 3,98x
Nbr of Employees 73 500
Free-Float 70,7%
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | MarketScreener
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 22
Last Close Price 78,33 $
Average target price 95,16 $
Spread / Average Target 21,5%
EPS Revisions
Managers and Directors
Robert M. Davis President, Chief Executive Officer & Director
Caroline A. Litchfield Chief Financial Officer & Executive Vice President
Kenneth C. Frazier Executive Chairman
Sandy Tremps Vice President-R&D IT CIO
Dave Williams Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
MERCK & CO., INC.-4.24%198 283
JOHNSON & JOHNSON2.49%424 619
ROCHE HOLDING AG16.59%339 442
NOVO NORDISK A/S54.22%234 792
PFIZER, INC.13.20%232 621